Tests modified T cells with or without nivolumab in adults with solid tumors
Tests modified T cells, alone or with nivolumab, in adults with PRAME-expressing solid tumors.
Key facts
- Who runs it
- Immatics US, Inc.
- Where
- Aurora, Boston, Chicago, Columbus, Houston, Miami, New York, Philadelphia, Pittsburgh, Seattle, and Stanford, United StatesSee the 13 sitesAlso in 1 other country, 8 sites
- Trial code
- Registry title
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 375 people, planned
- Started
- 14 May 2019
- Expected to end
- Jun 2032
- Type of study
- Interventional, 12 groups
- Treatments tested
- IMA203 Product
- IMA203 product- flat dose
- IMA203CD8 Product
- Nivolumab
- IMADetect®
- Record updated
- 13 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with solid tumors that came back, grew, or did not respond to treatment, and whose tumor shows the PRAME marker. They must also be HLA-A*02:01 positive.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Solid tumors that came back, are growing, or did not respond. People must have had or cannot have all standard treatments. Measurable disease (RECIST 1.1). Ovarian, fallopian tube or peritoneal cancer must be high-grade serous or endometrioid. Endometrial cancer must be recurrent or persistent.
- Earlier treatment
- Must have had, or not be able to have, all available standard treatments. Side effects of earlier treatment must be Grade 1 or lower before lymphodepletion. For nivolumab, no Grade 3 or 4 side effects from earlier PD1/PD-L1 inhibitor treatment.
- Biomarker or test result
- HLA-A*02:01 positive. The tumor must show the tumor antigen on the IMADetect® RT-qPCR test.
Main reasons for not taking part
- Another cancer within the last 3 years (some skin and in situ cancers excepted)
- Pregnant or breastfeeding
- Prior stem cell or solid organ transplant
- HIV infection, or active hepatitis B or C
- Active brain metastases
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- HLA-A*02:01 positive
- For patients with ovarian/fallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer
- For patients with endometrial carcinoma only: Patients must have a histologically confirmed diagnosis of recurrent or persistent endometrial carcinoma
- Measurable disease according to RECIST 1.1
- Adequate selected organ function per protocol
- Patient's tumor must express tumor antigen by "IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify
- Life expectancy more than 5 months
- Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8
- Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203/IMA203CD8
- The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion
Who cannot take part
- Prior stem cell transplantation or solid organ transplantation
- Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
- History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
- Concurrent treatment in another clinical trial
- For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.); Other protocol defined inclusion/exclusion criteria could apply
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
- Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents
- History of cardiac conditions as per protocol
- Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection
- Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA203/IMA203CD8 treatment
- Patients with LDH greater than 2.0-fold ULN
- Pregnant or breastfeeding
- Patients with active brain metastases
Where in United States
Also in 1 other country, 8 sites
- University of Colorado Anschutz Medical CampusAurora, United StatesContact: Sapna Patel, MDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Oldadapo O. Yeku, MD. PhDTaking people
- University of Chicago Medical CenterChicago, United StatesContact: Katherine Kurnit, MDTaking people
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill RunColumbus, United StatesContact: Casey Cosgrove, MDTaking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Dejka M Araujo, M.D.Taking people
- University of Miami Hospital and ClinicsMiami, United StatesContact: Immatics US, Inc.Taking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Alexander Shoushtari, MDTaking people
- Fox Chase Cancer CenterPhiladelphia, United StatesContact: Anthony Olszanski, MD, RPhTaking people
- Thomas Jefferson University, Honickman CenterPhiladelphia, United StatesContact: Rino Seedor, MDTaking people
- University of Pennsylvania, Perelamn Center for Advanced MedicinePhiladelphia, United StatesContact: Janos Tanyi, MD, PhDTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Diwakar Davar, M.D.Taking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Sylvia Lee, MDTaking people
- Stanford Cancer InstituteStanford, United StatesContact: Allison Warner, MDTaking people
About the trial
What the trial wants to find out
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
The 12 groups in the trial
- Dose Escalation A (closed to enrollment)Treatment being tested
Dose escalation of IMA203
Treatment: IMA203 Product and IMADetect®
- Extension Cohort ATreatment being tested
IMA203 at RP2D
Treatment: IMA203 Product and IMADetect®
- Extension Cohort B (closed to enrollment)Treatment being tested
IMA203 at RP2D + nivolumab
Treatment: IMA203 Product and Nivolumab
- Extension Cohort AATreatment being tested
IMA203 at final RP2D (flat dose)
Treatment: IMA203 product- flat dose and IMADetect®
- Uveal MelanomaTreatment being tested
IMA203 at RP2D
Treatment: IMA203 Product and IMADetect®
- Dose Escalation BTreatment being tested
Dose escalation of IMA203CD8
Treatment: IMA203CD8 Product and IMADetect®
- Extension Cohort CTreatment being tested
IMA203CD8 at dose levels confirmed to be safe
Treatment: IMA203CD8 Product and IMADetect®
- Extension Cohort DTreatment being tested
IMA203CD8 at dose levels confirmed to be safe; without IL-2
Treatment: IMA203CD8 Product and IMADetect®
- OvarianTreatment being tested
IMA203CD8 monotherapy at dose levels confirmed to be safe
Treatment: IMA203CD8 Product and IMADetect®
- EndometrialTreatment being tested
IMA203CD8 monotherapy at dose levels confirmed to be safe
Treatment: IMA203CD8 Product and IMADetect®
- Head and Neck, Lung, and Triple Negative Breast CancerTreatment being tested
IMA203CD8 monotherapy at dose levels confirmed to be safe
Treatment: IMA203CD8 Product and IMADetect®
- Rare CancersTreatment being tested
IMA203CD8 monotherapy at dose levels confirmed to be safe
Treatment: IMA203CD8 Product and IMADetect®
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
- Plain-language title
- Tests modified T cells with or without nivolumab in adults with solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 13 May 2026